Affordable Access

deepdyve-link
Publisher Website

Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary.

Authors
  • Papp, Kim A1, 2
  • Haraoui, Boulos3, 4
  • Kumar, Deepali3, 4
  • Marshall, John K3, 4
  • Bissonnette, Robert3, 4
  • Bitton, Alain3, 4
  • Bressler, Brian3, 4
  • Gooderham, Melinda3, 4
  • Ho, Vincent3, 4
  • Jamal, Shahin3, 4
  • Pope, Janet E3, 4
  • Steinhart, A Hillary3, 4
  • Vinh, Donald C3, 4
  • Wade, John3, 4
  • 1 From K. Papp Clinical Research; Probity Medical Research, Waterloo; University Health Network; Faculty of Medicine, University of Toronto; Mount Sinai Hospital, Toronto; Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton; Faculty of Medicine, Queen's University, Kingston; Faculty of Medicine, University of Western Ontario; St. Joseph's Health Care, London, Ontario; Centre Hospitalier de l'Université de Montréal; Innovaderm Research Inc.; McGill University Health Centre; Research Institute - McGill University Health Centre, Montreal, Quebec; Faculty of Medicine, University of British Columbia; St. Paul's Hospital; Vancouver Coastal Health; Vancouver General Hospital, Vancouver, British Columbia, Canada. [email protected] , (Canada)
  • 2 K.A. Papp, MD, PhD, FRCPC, K. Papp Clinical Research, and Probity Medical Research; B. Haraoui, MD, FRCPC, Centre Hospitalier de l'Université de Montréal; D. Kumar, MD, MSc, FRCPC, University Health Network, and Faculty of Medicine, University of Toronto; J.K. Marshall, MD, MSc, FRCPC, AGAF, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University; R. Bissonnette, MD, Innovaderm Research Inc.; A. Bitton, MD, FRCP, McGill University Health Centre; B. Bressler, MD, MS, FRCPC, Faculty of Medicine, University of British Columbia, and St. Paul's Hospital; M. Gooderham, MSc, MD, FRCPC, Probity Medical Research, and Faculty of Medicine, Queen's University; V. Ho, MD, FRCPC, Faculty of Medicine, University of British Columbia; S. Jamal, MD, FRCPC, MSc, Vancouver Coastal Health; J.E. Pope, MD, MPH, FRCPC, Faculty of Medicine, University of Western Ontario, and St. Joseph's Health Care; A.H. Steinhart, MD, FRCP(C), Faculty of Medicine, University of Toronto, and Mount Sinai Hospital; D.C. Vinh, MD, McGill University Health Centre, and Research Institute - McGill University Health Centre; J. Wade, MD, FRCP(C), Faculty of Medicine, University of British Columbia, and Vancouver General Hospital. [email protected]
  • 3 From K. Papp Clinical Research; Probity Medical Research, Waterloo; University Health Network; Faculty of Medicine, University of Toronto; Mount Sinai Hospital, Toronto; Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton; Faculty of Medicine, Queen's University, Kingston; Faculty of Medicine, University of Western Ontario; St. Joseph's Health Care, London, Ontario; Centre Hospitalier de l'Université de Montréal; Innovaderm Research Inc.; McGill University Health Centre; Research Institute - McGill University Health Centre, Montreal, Quebec; Faculty of Medicine, University of British Columbia; St. Paul's Hospital; Vancouver Coastal Health; Vancouver General Hospital, Vancouver, British Columbia, Canada. , (Canada)
  • 4 K.A. Papp, MD, PhD, FRCPC, K. Papp Clinical Research, and Probity Medical Research; B. Haraoui, MD, FRCPC, Centre Hospitalier de l'Université de Montréal; D. Kumar, MD, MSc, FRCPC, University Health Network, and Faculty of Medicine, University of Toronto; J.K. Marshall, MD, MSc, FRCPC, AGAF, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University; R. Bissonnette, MD, Innovaderm Research Inc.; A. Bitton, MD, FRCP, McGill University Health Centre; B. Bressler, MD, MS, FRCPC, Faculty of Medicine, University of British Columbia, and St. Paul's Hospital; M. Gooderham, MSc, MD, FRCPC, Probity Medical Research, and Faculty of Medicine, Queen's University; V. Ho, MD, FRCPC, Faculty of Medicine, University of British Columbia; S. Jamal, MD, FRCPC, MSc, Vancouver Coastal Health; J.E. Pope, MD, MPH, FRCPC, Faculty of Medicine, University of Western Ontario, and St. Joseph's Health Care; A.H. Steinhart, MD, FRCP(C), Faculty of Medicine, University of Toronto, and Mount Sinai Hospital; D.C. Vinh, MD, McGill University Health Centre, and Research Institute - McGill University Health Centre; J. Wade, MD, FRCP(C), Faculty of Medicine, University of British Columbia, and Vancouver General Hospital.
Type
Published Article
Journal
The Journal of Rheumatology
Publisher
The Journal of Rheumatology
Publication Date
Jul 01, 2019
Volume
46
Issue
7
Pages
751–754
Identifiers
DOI: 10.3899/jrheum.180784
PMID: 30709945
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

The use of immunosuppressive therapies for immune-mediated disease is associated with an elevated risk of infections and related comorbidities. While many infectious diseases can generally be prevented by vaccines, immunization rates in this specific patient population remain suboptimal, due in part to uncertainty about their efficacy or safety under these clinical situations. To address this concern, a multidisciplinary group of Canadian physicians with expertise in dermatology, gastroenterology, infectious diseases, and rheumatology developed evidence-based clinical guidelines on vaccinations featuring 13 statements that are aimed at reducing the risk of preventable infections in individuals exposed to immunosuppressive and immunomodulatory agents.

Report this publication

Statistics

Seen <100 times